

WHAT IS CLAIMED IS:

Sub A 1 1. A composition comprising a live attenuated *Streptococcus equi* and an immunostimulant, said immunostimulant having the property of stimulating mucosal immunity.

C 1 2. The composition of claim 1, wherein said *Streptococcus equi* is non-encapsulated.

C 1 3. The composition of claim 2, wherein said immunostimulant is saponin, metabolizable oil, bacterial toxoid, bacterial adjuvant, interleukin, interferon, carbopol, dextran derivative, dimethyldioctadecammonium bromide or a mixture thereof.

C 1 4. The composition of claim 3, wherein said immunostimulant is saponin.

a 1 5. The composition of claim 4, wherein said *Streptococcus equi* is strain 709-27, *(ATCC 53186)*

Sub B 2 6. The composition of claim 4, wherein said saponin is in the amount of from about 1 to about 10 mg/ml of said composition.

1 7. The composition of claim 4, wherein said saponin is in the amount of from about 3 to about 7 mg/ml of said composition.

1 8. The composition of claim 4, wherein said saponin is in the amount of from about 4 to about 6 mg/ml of said composition.

a 1 9. The composition of claim 4, wherein said *Streptococcus equi* is strain 709-27, *(ATCC 53186)* and said immunostimulant is saponin.

1 10. A dosage form for nasal administration comprising the
 2 composition of claim 1.

1 *Ind E3* 11. The dosage form of claim 10, wherein said *Streptococcus equi* is
 2 strain 709-27_A (*ATCC 53186*) and said immunostimulant is saponin.

Ind 82 12. The dosage form of claim 11, wherein said *Streptococcus equi* is
 2 present in a maximum dose of about 1×10^9 .

1 13. The dosage form of claim 11, wherein said *Streptococcus equi* is
 2 present in a minimum dose of about 1.7×10^7 .

Ind E4 14. The dosage form of claim 11 wherein said *Streptococcus equi* is
 2 in a lyophilized form and said saponin is in a diluent.

1 15. A method of stimulating an immune response to *Streptococcus*
 2 *equi* comprising contacting cells of the nasopharyngeal mucosa of an equine with a
 3 composition of claim 1.

Ind E5 16. The method of claim 15, wherein said *Streptococcus equi* is
 2 strain 709-27_A (*ATCC 53186*) and said immunomodulator is saponin.

1 17. A method for preventing at least one of the symptoms associated
 2 with *Streptococcus equi* infection in equine comprising administering an effective
 3 amount of the composition of claim 1 nasally or by mouth to said equine.

Ind E6 18. The method of claim 17, wherein said *Streptococcus equi* is
 2 strain 709-27_A (*ATCC 53186*) and said immunomodulator is saponin.

Ind E6 19. The method of claim 17, wherein said attenuated *Streptococcus*
 2 *equi* is in the amount of from about 10^5 to about 10^{11} *Colony forming Unit (CFU)*.

1 20. The method of claim 17, wherein said attenuated *Streptococcus*
2 *equi* is in the amount of from about 10^6 to about 10^{10} Colony Forming Unit (CFU).

1 21. The method of claim 17, wherein said attenuated *Streptococcus*
2 *equi* is in the amount of from about 10^7 to about 10^9 ^{Colony Forming Unit (CFU)}_{CFU}.

add 87

Digitized by Google